Literature DB >> 27165943

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma.

Nicolas Guibert1, Anne Pradines2, Anne Casanova2, Magali Farella2, Laura Keller2, Jean-Charles Soria3, Gilles Favre2, Julien Mazières4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27165943     DOI： 10.1016/j.jtho.2016.05.001

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  13 in total

Review 1.  Biology and clinical significance of circulating tumor cell subpopulations in lung cancer.

Authors:  Linda O'Flaherty; Harriet Wikman; Klaus Pantel
Journal:  Transl Lung Cancer Res       Date:  2017-08

2.  Association between clinical characteristics and the diagnostic accuracy of circulating single-molecule amplification and resequencing technology on detection epidermal growth factor receptor mutation status in plasma of lung adenocarcinoma.

Authors:  Chao Shi; Yan Zheng; Yin Li; Haibo Sun; Shilei Liu
Journal:  J Clin Lab Anal       Date:  2017-07-03       Impact factor: 2.352

Review 3.  Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer.

Authors:  Meysam Yousefi; Parisa Ghaffari; Rahim Nosrati; Sadegh Dehghani; Arash Salmaninejad; Yousef Jafari Abarghan; Seyed H Ghaffari
Journal:  Cell Oncol (Dordr)       Date:  2019-12-11       Impact factor: 6.730

4.  Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy.

Authors:  Menno Tamminga; Sanne de Wit; Ed Schuuring; Wim Timens; Leon W M M Terstappen; T Jeroen N Hiltermann; Harry J M Groen
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 5.  Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration.

Authors:  Lei Wang; Coraline Dumenil; Catherine Julié; Violaine Giraud; Jennifer Dumoulin; Sylvie Labrune; Thierry Chinet; Jean-François Emile; Biao He; Etienne Giroux Leprieur
Journal:  Oncotarget       Date:  2017-11-23

6.  Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma.

Authors:  Nicolas Guibert; Julien Mazieres; Myriam Delaunay; Anne Casanova; Magali Farella; Laura Keller; Gilles Favre; Anne Pradines
Journal:  Oncotarget       Date:  2017-06-06

Review 7.  Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.

Authors:  Julie A Vendrell; Frédéric Tran Mau-Them; Benoît Béganton; Sylvain Godreuil; Peter Coopman; Jérôme Solassol
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

8.  The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer.

Authors:  Mengyuan Lyu; Jian Zhou; Kang Ning; Binwu Ying
Journal:  Onco Targets Ther       Date:  2019-04-05       Impact factor: 4.147

Review 9.  Future perspectives from lung cancer pre-clinical models: new treatments are coming?

Authors:  Francesca Bersani; Deborah Morena; Francesca Picca; Alessandro Morotti; Fabrizio Tabbò; Paolo Bironzo; Luisella Righi; Riccardo Taulli
Journal:  Transl Lung Cancer Res       Date:  2020-12

Review 10.  Cell-Free DNA in Oncology: Gearing up for Clinic.

Authors:  Bryan C Ulrich; Cloud P Paweletz
Journal:  Ann Lab Med       Date:  2018-01       Impact factor: 3.464
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.